MX364946B - Sistema adyuvante mejorado para la administración de vacunas orales. - Google Patents
Sistema adyuvante mejorado para la administración de vacunas orales.Info
- Publication number
- MX364946B MX364946B MX2014011806A MX2014011806A MX364946B MX 364946 B MX364946 B MX 364946B MX 2014011806 A MX2014011806 A MX 2014011806A MX 2014011806 A MX2014011806 A MX 2014011806A MX 364946 B MX364946 B MX 364946B
- Authority
- MX
- Mexico
- Prior art keywords
- adminstration
- adjuvant system
- oral vaccine
- improved adjuvant
- compositions
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 229940126578 oral vaccine Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261686372P | 2012-04-04 | 2012-04-04 | |
| PCT/US2013/000102 WO2013151595A1 (en) | 2012-04-04 | 2013-04-03 | Improved adjuvant system for oral vaccine adminstration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014011806A MX2014011806A (es) | 2015-06-03 |
| MX364946B true MX364946B (es) | 2019-05-15 |
Family
ID=49300897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014011806A MX364946B (es) | 2012-04-04 | 2013-04-03 | Sistema adyuvante mejorado para la administración de vacunas orales. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20150079130A1 (OSRAM) |
| EP (2) | EP2833914B1 (OSRAM) |
| JP (1) | JP6240155B2 (OSRAM) |
| KR (1) | KR101867428B1 (OSRAM) |
| AU (1) | AU2013243971B2 (OSRAM) |
| CA (1) | CA2903313C (OSRAM) |
| DK (1) | DK2833914T3 (OSRAM) |
| IL (1) | IL234937B (OSRAM) |
| MX (1) | MX364946B (OSRAM) |
| WO (1) | WO2013151595A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015218769B2 (en) * | 2014-02-20 | 2020-09-17 | Vaxart, Inc. | Formulations for small intestinal delivery |
| WO2015192216A1 (en) * | 2014-06-20 | 2015-12-23 | University Of Saskatchewan | Exotoxin/thermolysin compositions and methods and uses for treating or preventing laminitis |
| CA2988761A1 (en) | 2015-06-12 | 2016-12-15 | Vaxart, Inc. | Formulations for small intestinal delivery of rsv and norovirus antigens |
| WO2017153316A1 (en) * | 2016-03-07 | 2017-09-14 | Glaxosmithkline Biologicals Sa | Drug delivery particles |
| BR112020021134A2 (pt) * | 2018-04-16 | 2021-03-23 | Merck Patent Gmbh | aditivos para formulações de proteínas para aprimorar estabilidade térmica |
| KR102369740B1 (ko) | 2020-09-21 | 2022-03-02 | 부경대학교 산학협력단 | 자궁경부암 조기진단을 위한 모바일 질확대경 장치 |
| WO2022094816A1 (en) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Solid formulation |
| CN113750228B (zh) * | 2021-09-25 | 2024-02-20 | 大连理工大学 | 一种冷冻保护剂在铝佐剂中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4133397A (en) * | 1996-10-28 | 1998-05-22 | Pfizer Inc. | Oral vaccines for young animals with an enteric coating |
| AU722326B2 (en) * | 1997-02-14 | 2000-07-27 | Merck & Co., Inc. | Polynucleotide vaccine formulations |
| US7087235B2 (en) | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
| US20030162955A1 (en) * | 1998-03-17 | 2003-08-28 | Lionel Chalus | Isolated mammalian membrane protein genes; related reagents |
| PT1093818E (pt) * | 1998-07-08 | 2006-07-31 | Kirin Amgen Inc | Preparacao em po para administracao nas mucosas contendo um medicamento polimerico |
| EP1046651A1 (en) * | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| JP4892705B2 (ja) * | 2002-08-20 | 2012-03-07 | オプサニテクス エルエルシー | レクチン組成物および抗原に対する免疫反応を調節するための方法 |
| US20040213745A1 (en) * | 2003-02-20 | 2004-10-28 | Vincent Sullivan | Powder formulations of rSEB for improved vaccination |
| GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
| CA2663851A1 (en) * | 2006-09-26 | 2008-04-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for enhancing an adjuvant |
| CN102573802A (zh) * | 2009-08-12 | 2012-07-11 | 希格默伊德药业有限公司 | 包含聚合物基质和油相的免疫调节组合物 |
| GB0919690D0 (en) * | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| GB201101665D0 (en) * | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
-
2013
- 2013-04-03 EP EP13772028.0A patent/EP2833914B1/en active Active
- 2013-04-03 KR KR1020147030919A patent/KR101867428B1/ko not_active Expired - Fee Related
- 2013-04-03 DK DK13772028.0T patent/DK2833914T3/en active
- 2013-04-03 JP JP2015504545A patent/JP6240155B2/ja active Active
- 2013-04-03 EP EP19151134.4A patent/EP3549605A1/en not_active Withdrawn
- 2013-04-03 CA CA2903313A patent/CA2903313C/en active Active
- 2013-04-03 WO PCT/US2013/000102 patent/WO2013151595A1/en not_active Ceased
- 2013-04-03 US US13/261,964 patent/US20150079130A1/en not_active Abandoned
- 2013-04-03 MX MX2014011806A patent/MX364946B/es active IP Right Grant
- 2013-04-03 AU AU2013243971A patent/AU2013243971B2/en not_active Ceased
-
2014
- 2014-10-02 IL IL234937A patent/IL234937B/en unknown
-
2018
- 2018-12-06 US US16/212,088 patent/US20190105389A1/en not_active Abandoned
-
2020
- 2020-11-05 US US17/090,292 patent/US20210052725A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013151595A1 (en) | 2013-10-10 |
| MX2014011806A (es) | 2015-06-03 |
| EP2833914A4 (en) | 2016-03-30 |
| KR20150002755A (ko) | 2015-01-07 |
| DK2833914T3 (en) | 2019-03-11 |
| EP2833914A1 (en) | 2015-02-11 |
| EP2833914B1 (en) | 2019-01-16 |
| KR101867428B1 (ko) | 2018-07-19 |
| EP3549605A1 (en) | 2019-10-09 |
| AU2013243971A1 (en) | 2014-10-02 |
| JP2015512441A (ja) | 2015-04-27 |
| IL234937A0 (en) | 2014-12-31 |
| AU2013243971B2 (en) | 2017-01-05 |
| CA2903313C (en) | 2019-10-22 |
| US20190105389A1 (en) | 2019-04-11 |
| US20150079130A1 (en) | 2015-03-19 |
| JP6240155B2 (ja) | 2017-11-29 |
| US20210052725A1 (en) | 2021-02-25 |
| IL234937B (en) | 2021-10-31 |
| CA2903313A1 (en) | 2013-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX364946B (es) | Sistema adyuvante mejorado para la administración de vacunas orales. | |
| MX2021000550A (es) | Forma de dosis orales de liberacion sostenida de tofacitinib. | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX348823B (es) | Formulaciones estables de linaclotida. | |
| MX2018002301A (es) | Composiciones de glucano y usos de las mismas. | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| BR112012029912A2 (pt) | vácinas de combinação de nanotransportadores sintéticos | |
| PH12014501991B1 (en) | Phenicol antibacterials | |
| IN2013MU03583A (OSRAM) | ||
| MD20170048A2 (ro) | Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| MX2015011109A (es) | Composiciones estables de activador de glucoquinasa. | |
| MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
| MX366829B (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| IN2013MU01177A (OSRAM) | ||
| MX2021003908A (es) | Polipeptidos de accion prolongada y metodos para su produccion y administracion. | |
| WO2014122671A3 (en) | Solid oral compositions of saxagliptin | |
| IN2013MU03422A (OSRAM) | ||
| IN2013MU03309A (OSRAM) | ||
| IN2013CH04314A (OSRAM) | ||
| IN2013MU03428A (OSRAM) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |